The overarching mission of the OHSU Department of Cell, Developmental & Cancer Biology is to advance the understanding of problems relevant to human health and disease. To accomplish this mission, research groups in the department have historically focused on questions regarding cell structure, organelles, life cycle, differentiation, and regulated communication between cells and extracellular signals and cues. An ultimate application of knowledge gained from these studies has been to understand important cell physiologic processes that effect human biology. These issues directly link to problems of interest to developmental biologists, including molecular and cellular mechanisms regulating tissue morphogenesis, tissue polarity and patterning. Read full welcome message here.
At AACR's Tumor Immunology and Immunotherapy event in November, CDCB research presented their research.
News and recognitions
Congratulations to Sara Courtneidge, Ph.D., who has been elected Fellow of the American Association for the Advancement of Science. Read more on OHSU Now.
Congratulations to Ferdinando Pucci, Ph.D., who has received over $600,000 in grants from the Collins Medical Trust, Medical Research Foundation, V Foundation, and Cancer Research UK in his first year at OHSU.
Recent CDCB publications:
Lind Lab published, Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway, in ASH's Blood Advances.
Congratulations to Sara Courtneidge, Ph.D., awarded the 18th Rosalind E. Franklin Award for Women in Science by the National Cancer Institute. Learn more about the award.
Congratulations to Nechiporuk Lab, for publishing Retrograde Ret signaling controls sensory pioneer axon outgrowth, in eLife.
Congratulations to Moran Lab for publishing OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function in The Journal of Immunology.
See profiles of CDCB faculty Melissa Wong, Ph.D., Amanda Lund, Ph.D., and Anupriya Agarwal, Ph.D., among others featured in Onward's Forces of Change.
Congratulations to Amanda Poissonnier, Ph.D., awarded a CRI/Irvington Postdoc Fellowship, a training fellowship from the Cancer Research Institute, for her project, Relieving immune suppressive pathways in breast cancer to improve outcomes.
Congratulations to Amanda Lund, Ph.D., chosen for the Cancer Research Institute's Lloyd J. Old STAR Program. Each STAR will receive $1.25 million over five years for research contributing to cancer immunotherapy.
Congratulations to Takahiro Tsujikawa, M.D., Ph.D., awarded as a best young physician scientist in Japan, by the Otorhinolaryngological Society of Japan. See photo
Recent CDCB publications:
Sherman Lab published, A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression, in AACR's Cancer Discovery.
Congratulations to Ryan Lane, recipient of the 2019 Outstanding Journal Article: Basic Science award, for his research article, IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin.
CDCB's Pepper Schedin, Ph.D., will be giving the talk, Young Women's Breast Cancer - What is the Role of Pregnancy? at the Susan G. Komen event, the 2019 Regional Breast Cancer Issues Conference.
View all CDCB news and recognitions.
CDCB is excited to welcome Ferdinando Pucci, Ph.D. Dr. Pucci is joining us as an assistant professor for Otolaryngology and for Cell, Developmental and Cancer Biology. His research area of interest is broadly in tumor immunology and tumor microenvironmental engineering. His research led him to follow tumor-derived extracellular vesicles to sinusoidal spaces in lymph nodes (LN), where he uncovered previously unappreciated paracrine influences on LN-macrophages and B cells, that together regulate tumor progression. Welcome, Ferdinando!
CDCB is pleased to announce that Joshua Walker, M.D., Ph.D., will be joining us as a joint faculty member in August. Dr. Walker is an assistant professor with Radiation Medicine. His primary research interests are to understand the mechanisms that underlie T cell dysfunction in cancer and to help develop multi-modality treatment regimens to prevent or reverse this dysfunction. His clinical training is in radiation oncology and much of his recent work has pursued a better understanding of how radiotherapy can be used with immunomodulation to stimulate/reactivate tumor-specific CD8 T cells. Welcome, Joshua!